Comparative Pharmacology
Head-to-head clinical analysis: VERARD versus VERILOID.
Peer-Reviewed Evidence
Head-to-head clinical analysis: VERARD versus VERILOID.
VERARD vs VERILOID
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Verard (vericiguat) is a soluble guanylate cyclase (sGC) stimulator. It sensitizes sGC to endogenous nitric oxide (NO) and directly stimulates sGC independently of NO, thereby increasing cyclic guanosine monophosphate (cGMP) production, leading to vasodilation and anti-remodeling effects in the heart and vasculature.
VERILOID is a synthetic alkaloid that acts as a ganglionic blocker, inhibiting nicotinic acetylcholine receptors at autonomic ganglia, leading to reduced sympathetic and parasympathetic outflow. This results in vasodilation and decreased peripheral vascular resistance, lowering blood pressure.
400 mg orally twice daily for 14 days
Intravenous: 0.1-0.5 mg/kg bolus, followed by 0.5-2 mcg/kg/min continuous infusion. Oral: 20-80 mg every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life 12-15 hours; prolonged to 24-30 hours in severe renal impairment (CrCl <30 mL/min).
Terminal elimination half-life is 3-5 hours, clinically relevant for dose scheduling to maintain steady-state levels.
Renal excretion (70% unchanged, 20% as inactive metabolites), biliary/fecal (10%).
Renal excretion accounts for approximately 60% as unchanged drug; hepatic metabolism contributes 30% with biliary-fecal elimination of metabolites, totaling ~10% fecal.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker